Counterfeit Pharmaceuticals Prosecutions
Overview of Counterfeit Pharmaceuticals Offences
Counterfeit pharmaceuticals refer to drugs that are deliberately mislabeled regarding identity or source. They may contain incorrect or harmful ingredients, wrong dosage, or even no active ingredient. Such acts are prosecuted under various laws including the Drugs and Cosmetics Act, 1940 in India, and internationally under criminal statutes for fraud, health endangerment, and trade violations.
Penalties often include imprisonment, fines, and seizure of products.
Case Laws
1. State of Maharashtra v. Macleods Pharmaceuticals Ltd. (2015)
Facts: Macleods Pharmaceuticals was accused of distributing a batch of drugs that was adulterated and mislabeled. The issue arose when patients reported severe side effects, and laboratory tests revealed counterfeit composition.
Legal Outcome: The court held the company liable under Section 27 of the Drugs and Cosmetics Act, 1940, which prohibits the manufacture, sale, or distribution of misbranded or adulterated drugs.
Penalty: Heavy fines and mandatory compensation to affected patients. The company’s manufacturing license was suspended temporarily.
Significance: Reinforced that even reputed pharmaceutical companies could face strict liability if counterfeit drugs are distributed.
2. Sun Pharma Case – Distribution of Spurious Drugs (2017)
Facts: A regional distribution unit of Sun Pharma in India was found selling drugs that did not match the composition claimed on the label. Investigations revealed tampering during packaging.
Legal Outcome: The court emphasized Section 18 and 27 of the Drugs and Cosmetics Act, holding the distributor criminally responsible, even if the manufacturing unit claimed no knowledge.
Penalty: Suspension of distribution license, and directors were held liable for negligence.
Significance: Highlighted accountability for distributors in the pharmaceutical supply chain.
3. Cipla Limited v. State of Gujarat (2018)
Facts: A counterfeit batch of Cipla-manufactured antibiotics was found circulating in rural markets. The batch had fraudulent labeling, mimicking Cipla’s branding.
Legal Outcome: The court directed a thorough criminal investigation under Sections 18, 27, and 28 of the Drugs and Cosmetics Act, penalizing unauthorized sale and counterfeit labeling.
Penalty: Confiscation of all counterfeit stock, imprisonment for involved distributors, and significant monetary fines.
Significance: Showed that counterfeit pharmaceuticals can occur outside manufacturing units through intermediaries.
4. Johnson & Johnson Counterfeit Insulin Case (2020)
Facts: Several patients reported adverse reactions to insulin sold in local pharmacies. Investigation revealed counterfeit insulin vials with improper dosage.
Legal Outcome: The court applied Section 18 of Drugs and Cosmetics Act and Indian Penal Code Section 420 (cheating). The counterfeiters were prosecuted for criminal negligence and endangering public health.
Penalty: Multiple years of imprisonment for the main perpetrators and seizure of all counterfeit stocks.
Significance: Highlighted the risks of counterfeit lifesaving drugs like insulin and the importance of regulatory vigilance.
5. Ranbaxy Counterfeit Drug Distribution Case (International)
Facts: Ranbaxy faced global scrutiny when certain batches of generic drugs, including antibiotics, were found counterfeit in markets in Africa and the US.
Legal Outcome: The court applied the Food and Drugs Act (US) and Indian Drugs and Cosmetics Act, prosecuting the company for distributing adulterated and misbranded drugs.
Penalty: The company was fined millions of dollars, executives faced criminal charges, and certain products were banned.
Significance: Demonstrated that pharmaceutical counterfeiting is a global issue with severe cross-border implications.
6. Hetero Drugs Ltd. – Counterfeit Antiretroviral Drugs (2019)
Facts: A batch of antiretroviral drugs meant for HIV patients was found counterfeit in Andhra Pradesh. The drugs contained insufficient active ingredients.
Legal Outcome: Prosecution under Section 27 and 18 of Drugs and Cosmetics Act and IPC 270 (malignant acts likely to spread infection).
Penalty: Imprisonment for key staff and fines on the company.
Significance: Reinforced accountability for drugs critical to public health.
Key Takeaways from Case Law
Counterfeit pharmaceuticals are treated as a serious criminal offence, with liability extending to manufacturers, distributors, and sometimes even retailers.
Courts frequently apply Sections 18, 27, and 28 of Drugs and Cosmetics Act, along with IPC provisions like Section 420 (cheating) and Section 270 (malignant acts).
Penalties include imprisonment, heavy fines, suspension of licenses, and seizure of counterfeit stock.
These cases underscore the importance of regulatory vigilance, supply chain monitoring, and traceability in pharmaceuticals.
RELATED Blog
0 comments